Abstract
Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Current Gene Therapy
Title:Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect
Volume: 15 Issue: 6
Author(s): Mirella Meregalli, Andrea Farini, Clementina Sitzia, Cyriaque Beley, Paola Razini, Letizia Cassinelli, Federica Colleoni, Paola Frattini, Nadia Santo, Elisabetta Galbiati, Davide Prosperi, Alessandro Tavelli, Marzia Belicchi, Luis Garcia and Yvan Torrente
Affiliation:
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Abstract: Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Export Options
About this article
Cite this article as:
Meregalli Mirella, Farini Andrea, Sitzia Clementina, Beley Cyriaque, Razini Paola, Cassinelli Letizia, Colleoni Federica, Frattini Paola, Santo Nadia, Galbiati Elisabetta, Prosperi Davide, Tavelli Alessandro, Belicchi Marzia, Garcia Luis and Torrente Yvan, Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect, Current Gene Therapy 2015; 15 (6) . https://dx.doi.org/10.2174/1566523215666150929111400
DOI https://dx.doi.org/10.2174/1566523215666150929111400 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and In Vitro Anticancer Activity of Novel 2-((3-thioureido)carbonyl) phenyl Acetate Derivatives
Letters in Drug Design & Discovery Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters The HAG Mechanism: A Molecular Rationale For The Therapeutic Application Of Iron Chelators In Human Diseases Involving the 2-Oxoacid Utilizing Dioxygenases
Current Medicinal Chemistry From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design A Review of the Chemical and Pharmacological Aspects of the Genus Marrubium
Current Pharmaceutical Design Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Neoplastic Conditions in the Context of HIV-1 Infection
Current HIV Research Non-Traditional Drug Targets: High Risk, High Reward
Current Gene Therapy Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Peptide-Based Subunit Nanovaccines
Current Drug Delivery Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Prevalence and Distribution of Human Papillomavirus Genotype in South Eastern Italy, in the Period 2006-2011: Implications for Intervention
Current Pharmaceutical Design Use of Lactobacilli and their Pheromone-Based Regulatory Mechanism in Gene Expression and Drug Delivery
Current Pharmaceutical Biotechnology Hybrid Imaging in Evaluation of Abdominal Sarcoidosis
Current Medical Imaging Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Chitosan and Quercetin: Potential Hand in Hand Encountering Tumors in Oral Delivery System
Current Pharmaceutical Design Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science